Assets

VLS-01

atai Therapeutics

Molecule class

DMT, buccal film formulation (acquirer release)

Mechanism

Not independently verified. See A001 note.

Phase

Phase 2b complete: NCT06524830 (ELUMINA) COMPLETED on ClinicalTrials.gov, primary completion 2026-07-30 ACTUAL, study completion 2026-10-16 ACTUAL, enrollment 142 ACTUAL, record last updated 2026-10-30, no results posted as of 2026-11-02; last patient dosed 2026-07-06; Phase 3 in MDD planned

Indication

treatment-resistant depression; planned MDD

Sponsor geography

US

Next catalyst

Phase 3 initiation; CVR milestone one pays up to $1.00 per CVR if a Phase 3 of VLS-01 is initiated before the 4th anniversary of the 2026-09-11 Closing Date, by 2030-09-11

Partner

Eli Lilly and Company (acquisition closed 2026-09-11)

IP status

Not checked. Recorded as unchecked rather than left blank.

The catalyst above is recorded as reported, not verified. It is this publication's reading of the company's guidance, not a date the company has published.

clinicaltrials.govregistryverified 2026-11-02